Shelf life (days): 730.0
Formulation: A film
Formal Name: N-[(1S,2R,3E)-1-[[[O-(N-acetyl-a-neuraminosyl)-(2?3)-O-ß-D-galactopyranosyl-(1?4)-ß-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-hexadecanamide-13,13,14,14,15,15,16,16,16-d9, monosodium salt
Purity: ≥99% deuterated forms (d1-d9); ≤1% d0
Formula Markup: C57H94D9N2O21 / NH4
Formula Weight: 1179.5
Notes: C16 Ganglioside GM3-d9 (d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 ganglioside GM3 by GC- or LC-MS. C16 Ganglioside GM3 (d18:1/16:0) is a monosialylated ganglioside. It has been found in human fetal frontal lobe tissue isolated in the 27th gestational week but not in human fetal anencephalic residual brain tissue isolated in the 28th gestational week.{53905} C16 Ganglioside GM3 (d18:1/16:0) is higher in the serum of patients with visceral fat accumulation (VFA) and patients with VFA and dyslipidemia compared to healthy lean control subjects.{53906} Serum levels of C16 ganglioside GM3 (d18:1/16:0) are inversely correlated with erythrocyte counts in patients with hematological diseases, including patients with lymphoid neoplasms.{53907}This product is fully synthetic and has no variations in the fatty acyl chain or sphingoid backbone. It is intended for use as an analytical standard for the quantification of [C16 ganglioside GM3] by mass spectrometry.
English
Deutsch
